AstraZeneca Streamlines Portfolio with Four More Externalisation Deals

By Keshav Mahawar

Pharma Deals Review: Vol 2016 Issue 10 (Table of Contents)

Published: 21 Oct-2016

DOI: 10.3833/pdr.v2016.i10.2203     ISSN: 1756-7874

Section: Licensing



Continuing its strategy of offloading non-core products in order to prioritise its resources on key growth areas, AstraZeneca (AZ) has out-licensed its Phase IIb inflammatory disease asset MEDI2070 to Allergan and granted Insmed global rights to Phase II-ready AZD7986 for non-cystic fibrosis bronchiectasis...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details